Brind.

Rallybio and Recursion initiated preclinical studies for the compound REV102.

2 reports, 1 independent Updated Sep 3

Gone quiet

Reports: 2
Developments: 2
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Rallybio and Recursion initiated preclinical studies for the compound REV102.

Who's involved

What this event is mainly about

Rallybio Recursion (United States)

How it developed

Newest first. Tap a step to see who reported it.

Sep 3Rallybio and Recursion started preclinical studies for REV102.1 source
- Business Wire
Aug 7Rallybio sold its interest in the preclinical asset REV102.1 source
- Business Wire

Keep exploring

The entities involved

Rallybio
American biotechnology company
- Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.Sun 04:48
Recursion (United States)
company in Salt Lake City, United States
- Recursion (United States) disclosed insider trading via required filings with the SEC on June 6, 2026.Sun 17:12
- Trump's pledge to unleash oil and gas benefits stocks, involving Willis Towers Watson.Sun 05:14

Coverage

Newest first; wire copies grouped

Sep 3Business WireRallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program – Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a P
Aug 7Business WireRallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates – Data Readouts from Cohort 1 and Cohort 2 of RLYB116 Confirmatory PK/PD Study on Track for 3Q and 4Q 2025, Respec